Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q3 2021 · 10-Q
Revenue$8.82K$8.82K−70.4% vs Q3 2020 Net Income-$1.36M-$1.36MN/M vs Q3 2020 EPS Diluted-$0.21-$0.21N/M vs Q3 2020 Operating Income-$1,634,649N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-18539.7%−11653.0 pt vs Q3 2020
Net margin-15461.5%−12827.5 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end